News
IRWD
15.03
-0.27%
-0.04
Weekly Report: what happened at IRWD last week (0219-0223)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), AMN Healthcare Services (AMN) and Ironwood Pharma (IRWD)
TipRanks · 1d ago
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
Ironwood Pharmaceuticals will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) The company will present at the American Society for Parenteral and Enteral Nutrition 2024 Nutrition Science & Practice Conference. SBS is a serious and chronic condition resulting from extensive intestinal resection.
Barchart · 4d ago
Weekly Report: what happened at IRWD last week (0212-0216)?
Weekly Report · 02/19 09:15
Ironwood Pharmaceuticals CEO & Director Thomas McCourt Sells 39% Of Holding
Thomas McCourt, the CEO & Director of Ironwood Pharmaceuticals, Inc. Recently sold shares for US$2.7m. This is the biggest insider sale in the last year at the average price of US$15.24. Over the last 12 months we see more insider selling of ironwood pharmaceuticals shares than buying. Insiders own 1.8% of the company. But the company is not a good place to buy. You can see the insider transactions at ironwood pharmaceuticals in the UK.
Simply Wall St · 02/18 13:55
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Ironwood Pharmaceuticals, Inc. Shares have gained 28% in the last month. The company's price-to-sales ratio is 5.4x compared to the wider Biotechs industry. The stock is up 32% in last year but still trails the rest of the industry in the U.S. With a low revenue growth rate. With a low P/S ratio, investors are expecting low future growth from the company.
Simply Wall St · 02/16 19:07
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
NASDAQ · 02/16 14:36
Ironwood Pharma: A Strong Buy on Solid Financials and a Promising Pipeline
TipRanks · 02/15 19:45
Ironwood Pharmaceuticals Receives ‘Buy’ Rating from Analyst Amid Strong Performance and Promising Drug Pipeline
TipRanks · 02/15 19:06
Top 4 Health Care Stocks You May Want To Dump In February
Four stocks in the health care sector are overbought as of Feb. 15, 2024. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength. An asset is typically considered to be overb bought when the RSI value is above 70.
Benzinga · 02/15 13:15
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
NASDAQ · 02/15 13:15
Ironwood Pharmaceuticals Q4 Sales $117.55M Beat $117.48M Estimate, Generated $35.8M In Cash From Operations In Q4
Benzinga · 02/15 12:10
More
Webull provides a variety of real-time IRWD stock news. You can receive the latest news about Ironwood through multiple platforms. This information may help you make smarter investment decisions.
About IRWD
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company, which is advancing the treatment of GI diseases and redefining the standard of care for GI patients. It develops and commercializes GI product opportunities in areas of unmet need, leveraging its expertise and capabilities in GI diseases. LINZESS (linaclotide), its commercial product, is a class of GI medicines called guanylate cyclase type C agonists (GC-C agonists) and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company is also advancing apraglutide, a synthetic peptide analog of glucagon-like peptide-2 (GLP-2), for rare GI diseases, including short bowel syndrome with intestinal failure (SBS-IF).